MOG antibody-associated disease (MOGAD)
Myelin oligodendrocyte glycoprotein antibody disease · Neurology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
An inflammatory demyelinating disorder defined by serum MOG-IgG, presenting with optic neuritis, transverse myelitis, ADEM or brainstem syndromes. Distinct from MS and NMOSD, it is usually steroid-responsive but relapse-prone in a subset, requiring tailored immunotherapy.
Red flags
- Severe bilateral or sequential optic neuritis with vision loss
- Longitudinally extensive transverse myelitis with respiratory/sphincter involvement
- Encephalopathy (ADEM-like)
- Relapse during steroid taper
- Diagnostic confusion with NMOSD (different treatment)
Assessment
Differential diagnosis
- Multiple sclerosis
- Neuromyelitis optica spectrum disorder (AQP4 antibody)
- Acute disseminated encephalomyelitis
- Infectious/para-infectious optic neuritis or myelitis
- Sarcoidosis
- Ischaemic optic neuropathy
Investigations
- Serum MOG-IgG by cell-based assay (and AQP4-IgG to exclude NMOSD)
- MRI brain, orbits and whole spine with contrast
- Lumbar puncture (oligoclonal bands usually absent, unlike MS)
- Visual acuity, fields and OCT for optic neuritis
- Exclude infection and systemic inflammatory mimics
- Repeat MOG-IgG after the acute phase to assess persistence
Management
- Recognise optic neuritis, myelitis, ADEM or brainstem syndrome with supportive MRI
- Send MOG-IgG and AQP4-IgG by cell-based assay before or alongside treatment
- Treat the acute attack with high-dose intravenous corticosteroids
- Add plasma exchange or IVIG for severe or steroid-refractory attacks
- Taper oral steroids slowly, as rapid withdrawal can trigger relapse
- Assess relapse risk (persistent MOG-IgG, relapsing course)
- Start maintenance immunotherapy for relapsing disease
- Avoid MS disease-modifying drugs which are ineffective or harmful in MOGAD
- Monitor vision and neurological function longitudinally
- Provide relapse-recognition advice and rapid access to care
Drugs & doses
Methylprednisolone 1 g IV daily for 3-5 days (acute attack)
Oral prednisolone taper over weeks to months after IV course
Plasma exchange (5-7 exchanges) for severe/refractory attacks
IVIG 2 g/kg for acute treatment or maintenance
Maintenance: rituximab, azathioprine, mycophenolate or regular IVIG for relapsing disease
Disposition
Specialist neuroimmunology/MS service. Acute admission for treatment. Long-term immunotherapy for relapsing disease.
Complications & pitfalls
- Permanent visual loss
- Residual myelopathy and bladder dysfunction
- Relapse during or after steroid withdrawal
- Immunosuppression-related infection
- Cognitive sequelae after ADEM
Exam pearls
- Low-titre or negative MOG-IgG should prompt caution; use a validated cell-based assay
- Slow steroid tapers reduce early relapse risk
- Do not use MS disease-modifying therapies (interferon, natalizumab) in MOGAD
- Oligoclonal bands are usually absent, unlike multiple sclerosis
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.